Author Archives: David C. Whitcomb, Celeste Shelton, Randall E. Brand

Genetic testing of germline DNA is used in patients suspected of being at risk of pancreatic ductal adenocarcinoma (PDAC) to better define the individual’s risk and to determine the mechanism of risk. A high genetic risk increases the pretest probabi… Continue reading →